ADC Therapeutics SA (ADCT) Tops Q1 EPS by 18c

ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.22), $0.18 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.03 million versus the consensus estimate of $17.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• NVIDIA (NVDA) call put ratio 1.9 calls to 1 put with a focus on 5K contracts of October 160 puts
• L3Harris CEO steps down amid conduct review, shares drop